Hashimoto Clinic, 3-21-5 Hashimoto Midori-ku, Sagamihara, Kanagawa, 252-0143, Japan.
J Artif Organs. 2020 Sep;23(3):296-301. doi: 10.1007/s10047-020-01164-1. Epub 2020 Mar 30.
Two dialysis patients developed recurrent restless legs syndrome. The clinical courses and the association between the α-microglobulin removal rate and the therapeutic effects of hemodiafiltration were analyzed. Case 1: a middle-aged woman was switched from predilution online hemodiafiltration to hemodialysis, following which the α-microglobulin removal rate decreased from 39.1 to 29.9%. A month later, the severe restless legs syndrome occurred. The treatment was then switched to high-efficiency hemodiafiltration and 2 weeks later, these symptoms were resolved. The α-microglobulin removal rate increased to 41.9%. Her symptoms recurred 5 years later with severity; thus, the hemodiafiltration treatment conditions were changed. Under revised conditions, the α-microglobulin removal rate was 42.6%, and her symptoms were alleviated. Continuation of high-efficiency hemodiafiltration led to the resolution of the syndrome at 1 month after recurrence. Case 2: a middle-aged man on hemodialysis developed the restless legs syndrome in the second year of treatment. The α-microglobulin removal rate was 23.8%. After switching to a month-long high-efficiency hemodiafiltration with a removal rate of ≥ 40%, his symptoms were resolved. However, the syndrome recurred after a year with severity. The symptoms were alleviated using various measures. The hemodiafilters were changed, and hemodiafiltration with an α-microglobulin removal rate of ≥ 40% was continued; 2 months later, his symptoms resolved. High-efficiency online hemodiafiltration is an effective therapeutic strategy for restless legs syndrome in dialysis patients. We found, for the first time, that target removal efficiency is an α-microglobulin removal rate of 40% or higher.
两名透析患者出现复发性不安腿综合征。分析了临床过程和α-微球蛋白清除率与血液透析滤过治疗效果之间的关系。病例 1:一名中年女性由预稀释在线血液透析滤过转换为血液透析后,α-微球蛋白清除率从 39.1%降至 29.9%。一个月后,严重的不安腿综合征发作。随后治疗转换为高效血液透析滤过,两周后,这些症状得到缓解,α-微球蛋白清除率增加至 41.9%。5 年后,她的症状再次发作且加重,因此更改了血液透析滤过治疗条件。在修订后的条件下,α-微球蛋白清除率为 42.6%,症状得到缓解。继续高效血液透析滤过导致综合征在复发后 1 个月得到缓解。病例 2:一名中年男性在血液透析治疗的第二年出现不安腿综合征,α-微球蛋白清除率为 23.8%。转换为持续一个月的高效血液透析滤过,清除率≥40%后,其症状得到缓解。然而,一年后,症状严重复发。使用各种措施缓解症状。更换血液透析滤器,继续使用α-微球蛋白清除率≥40%的血液透析滤过;2 个月后,症状缓解。高效在线血液透析滤过是透析患者不安腿综合征的有效治疗策略。我们首次发现,目标清除效率为α-微球蛋白清除率 40%或更高。